Journal article
Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics
- Abstract:
-
Inhibition of sclerostin is a therapeutic approach to lowering fracture risk in patients with osteoporosis. However, data from phase 3 randomized controlled trials (RCTs) of romosozumab, a first-in-class monoclonal antibody that inhibits sclerostin, suggest an imbalance of serious cardiovascular events, and regulatory agencies have issued marketing authorizations with warnings of cardiovascular disease. Here, we meta-analyze published and unpublished cardiovascular outcome trial data of romos...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Authors
Funding
Bibliographic Details
- Publisher:
- American Association for the Advancement of Science Publisher's website
- Journal:
- Science Translational Medicine Journal website
- Volume:
- 12
- Issue:
- 549
- Article number:
- eaay6570
- Publication date:
- 2020-06-24
- Acceptance date:
- 2020-05-26
- DOI:
- EISSN:
-
1946-6242
- ISSN:
-
1946-6234
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
1112307
- Local pid:
- pubs:1112307
- Deposit date:
- 2020-06-15
Terms of use
- Copyright holder:
- Bovijn et al.
- Copyright date:
- 2020
- Rights statement:
- © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works
- Notes:
- This is the accepted manuscript version of the article. The final version is available from American Association for the Advancement of Science at: https://doi.org/10.1126/scitranslmed.aay6570
If you are the owner of this record, you can report an update to it here: Report update to this record